 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | TB Healthcare |
| Street 1: | Sino-European Services Center A1 |
| Street 2: | Foshan New City |
| City: | Foshan |
| Province: | Guangdong |
| Post Code: | 528000 |
| Country: | China |
| Phone: | 86-757-2939-8836 |
| Organization Email: | contact@tbhealthcare.com |
| Web Site: | http://en.tbhealthcare.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Health |
| Organization Description: | |
| 1. TB Healthcare, based in Foshan, Guangdong province, China, was formed in 2013 to develop and bring to market a range of products for use within the healthcare industry that will contribute to the prevention, diagnosis and treatment of tuberculosis, both within China and worldwide. 2. Our interest in tuberculosis is linked with our history. TB Healthcare is a spin-off company originally founded by a consortium of TB-focused research groups in China whose desire was to focus research efforts on providing solutions for real clinical problems encountered in the prevention, treatment and control of TB. 3. We have developed a series of products including the MtbProtTM M. tuberculosis proteome microarray and associated protein library, improved diagnostic kits (for TB diagnosis and drug sensitivity testing) and related equipment, and have the long-term goal of developing a new TB vaccine and antibiotics. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 100 + |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Attendance at a TB related event |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| The goals of TB Healthcare match well with China's national TB control plan. We are developing products that address some of the roadblocks within the TB prevention and control system, both in China and worldwide. Our microarray products are experimental platforms that have potential to greatly accelerate research on Mycobacterium tuberculosis and are already being applied both clinically, by drug development companies and more generally within the TB research community. BACspreaderTM is a newly developed instrument that can simultaneously perform declumping of bacterial colonies and turbidity measurements and was originally designed for application in clinical TB diagnostic labs. A range of diagnostic kits are being developed to improve the accuracy of TB diagnosis and DST assessment in clinical situations, some of which will reach the market at the beginning of 2017. Our work on TB vaccine development has received support at the national level. | |
Geographical Reach | |
| Which country is your headquarters located in: | China |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
China |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: Our research team performed a genomic analysis of 200+ isolates of Mycobacterium tuberculosis with varying levels of drug resistance in order to provide a more comprehensive understanding of the genetic basis of drug resistance. This work was published in Nature Genetics in 2013 (Zhang et al., Nature Genetics 45, 1255–1260). Since then we have been developing diagnostic kits to speed up the process DST testing. These kits are currently under clinical assessment and we expect they will be available in China in 2017. Laboratory Strengthening: We have designed a new piece of equipment, BACspreaderTM, to simplify the process of declumping colonies and making turbidity measurements. This piece of equipment greatly reduces user exposure to biological hazards as all operations are performed within a closed system, thus improving lab safety. New Diagnostics: We have completed the development of a series of diagnostic kits to improve the accuracy of TB diagnosis and DST testing. These are based on antibodies of protein biomarkers screened using our MtbProtTM proteome microarray. The kits are undergoing clinical assessment and approval by the China FDA. The first set of kits should reach the market at the beginning of 2017. New TB Drugs: Our drug development program spans selection of lead compounds, drug target identification, functional analysis and compound optimization. New TB Vaccines: We have performed a genome-wide analysis of humoral and cellular immunogens, and have identified >20 new candidate vaccine antigens. We are assessing these new antigens using a guinea-pig model and candidates which show protective immune responses will be tested further and go into clinical trials for vaccine development. Fundamental Research: We are connected to a Consortium of Chinese research groups and clinical partners working on TB whose research ranges from basic research on aspects such as protein structural biology, non-coding RNA and genomics, to more applied aspects such as drug resistance and vaccine development. Research: We are connected to a Consortium of Chinese research groups and clinical partners working on TB whose research ranges from basic research on aspects such as protein structural biology, non-coding RNA and genomics, to more applied aspects such as drug resistance and vaccine development. |
|
Declaration | |
| Declaration of interests: We are not aware of any conflicts of interest. | |
| Application date: | June 7, 2016 |
| Last updated: | May 14, 2018 |